Innovative Biotech Plays

Some scientists believe that we’re in the "golden age" of biotechnology. Scientific advances are creating new ways, previously only imaginable, to treat and prevent diseases. The biotech sector is also presenting exciting opportunities for investors. Many of the best biotech companies have both strong drug candidate pipelines and winning drugs already on the market. The COVID-19 pandemic has also created massive opportunities for biotechnology companies that are developing treatments and vaccines for the virus.

Investing in biotech stocks can be risky because it's possible that a company's drug candidate proves ineffective or worse in clinical testing. And, even if testing goes well, biotech companies have no guarantee that a drug will be approved by the FDA. The least risky biotech companies have drugs already commercially available and many drugs in later phases of testing. The best biotech companies also develop drug candidates with peak annual sales that are forecast to be high.

You can reduce your investment risk by focusing on biotech companies with strong financial positions. Biotech companies that already sell one or more drugs are much more likely to be profitable, and they are less likely to use creative means to generate the significant amounts of cash required to fund drug research and development. Biotech companies that are unprofitable are at risk of not having enough money to successfully fund clinical studies and complete regulatory filings to bring a new drug to market. The best biotech companies are well-positioned to deliver tremendous returns over long periods of time, making them well-suited for buy-and-hold investors.

Axsome's (NASDAQ: AXSM) lead drug candidate, which it calls AXS-05, targets depression, Alzheimer’s disease-related agitation, and cigarette smoking cessation. In early 2021, the company filed for U.S. regulatory approval for the drug to treat depression. FDA identified two manufacturing deficiencies in Axsome’s regulatory filing, but Axsome believes the issues are addressable and is working with the FDA to resolve them.

The company’s pipeline includes two other late-stage candidates. AXS-07 targets the treatment of migraines, and the FDA is scheduled to make an approval decision on the investigational drug in 2022. In 2023, Axsome expects to file for U.S. regulatory approval of AXS-14 for treating fibromyalgia. If approved, AXS-05 as a depression treatment could be a blockbuster drug, with peak annual sales, the highest dollar volume of sales per year projected by analysts, estimated at $2.6 billion. The revenue potential for these three drug candidates makes Axsome Therapeutics an attractive biotech stock to consider buying in 2022.

Revenues from the global SCI therapeutics market reached $6.7 billion in 2021, and between 2021 and 2028, it is anticipated to expand at a rate of 5.1 percent per year. Therefore, it makes sense why investors and the world's SCI patients are so interested in the huge potential that exosomes provide both new and existing SCI patients. Continue reading to find out more about NurExone, an Israeli-Canadian biotech company with a focus on exosomes that has achieved particularly encouraging results with their non-invasive SCI treatment.

The goal of NurExone (TSXV: NRX) is to fill this unmet market demand for medicines for SCI that are secure, effective, and practical. The business is creating an exosome-based biological treatment for SCIs that has the potential to be a ground-breaking, non-invasive "off the shelf" medication. Exosomes are tiny bubbles that move substances from one cell to another. Exosome therapy has the potential to revolutionize the field of regenerative medicine since it enhances cell-to-cell communication and promotes healing. Exosome-based SCI therapy from NurExone is administered intranasally, making it comfortable for both patients and medical professionals.

In the world of regenerative medicine, NurExone's ground-breaking exosome-based medication platform is making waves, and for good reason. With a treatment, the company hopes to penetrate the SCI market and significantly raise the standard of living for millions of SCI sufferers. Initial findings support the company's potential: The company's technology has the potential to revolutionize the SCI market, according to trials on rats by NurExone that recovered motor function. In light of its intriguing biotechnology portfolio and solid cooperation with one of Israel's top universities, NurExone stands out as an up-and-coming exosomes leader.

By issuing new shares of stock, which lowers the value of the current shares, many developing biotech companies frequently generate cash. Some biotechnology firms also receive funding from grants from governmental bodies and nonprofit organizations, as well as money earned through agreements with larger pharmaceutical companies. The biotech industry frequently engages in mergers and acquisitions, making it possible for even the most promising biotech businesses to be acquired by their more established rivals. In short, this is the time to get involved!